Security Snapshot

Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value per share (VRCA) Institutional Ownership

CUSIP: 92511W207

13F Institutional Holders and Ownership History from Q2 2025 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

14

Shares (Excl. Options)

1.52MFull value: 1,521,318 · shares · 30 Sep 2026

Price

$4.80

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, $0.0001 par value per share
Symbol
VRCA on Nasdaq
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
1,521,318
Latest holder snapshot 5 signals
Total 13F value
$7,270,846
Portfolio coverage rank
0%
Share change
+33,169
Value change
+$140,435
Number of holders
14
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
17,344,449
SEC-reported price per share
$4.80
Insider filing price
$4.80
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • VRCA - Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 92511W207.
  • 14 institutions reported positions in Q3 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 43 to 14 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $28.54MFull value: $28,535,134 · USD · 30 Jun 2026
    to
    $7.27MFull value: $7,270,846 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 14 institutions filings for Q3 2026.

Open SEC evidence

Security key

92511W207

13F reference period

Q3 2026

13F holders

14

13D/G owners

4

CIK / CUSIP context first

Open Q3 2026 holders VRCA full holder history Verrica Pharmaceuticals Inc. SEC filings Verrica Pharmaceuticals Inc. company facts Verrica Pharmaceuticals Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
4
Security
VRCA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Manning Paul B 50% $28,437,789 8,056,031 Paul B Manning 25 Nov 2025
Caligan Partners LP 10% 0% $43,635,492 6,503,054 0% Caligan Partners LP 26 Dec 2025
Affinity Asset Advisors, LLC 5% -8.5% $4,150,015 -$89,590 865,488 -2.1% Affinity Asset Advisors, LLC 30 Sep 2026
ARMISTICE CAPITAL, LLC 5% -25% $3,649,153 -$1,656,149 439,657 -31% Armistice Capital, LLC 31 Dec 2025
As of 30 Sep 2026, 14 institutional investors reported holding
1.52MFull value: 1,521,318 · shares · 30 Sep 2026
shares of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value per share (VRCA). This represents 8.8% of the company’s total
17.34MFull value: 17,344,449 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
6
Headline period
Q3 2026
Rows shown
1-6 of 6
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 1,521,318 $7,270,846 +$140,435 $4.80 14
2026 Q2 4,662,624 $28,535,134 -$445,500 $6.12 43
2026 Q1 4,777,869 $25,275,078 -$4,207,213 $5.29 39
2025 Q4 5,196,096 $43,155,907 +$20,755,741 $8.31 49
2025 Q3 2,468,945 $10,583,119 +$10,479,755 $4.31 31
2025 Q2 194,004 $102,830 +$102,830 $0.53 4
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .